Bioprocess Containers Market Seen Reaching $22.19 Billion by 2030

The bioprocess containers market is projected to grow from $6.39 billion in 2025 to $22.19 billion by 2030, driven by biologics, biosimilars and single-use sterile processing systems. North America led in 2025, while Asia-Pacific is expected to grow fastest as biomanufacturing expands.

Why it matters: - Bioprocess containers are a core part of sterile biopharmaceutical manufacturing. - Demand is rising as drugmakers scale biologics, biosimilars and cell and gene therapy production. - The market’s projected jump to $22.19 billion by 2030 signals continued investment in flexible, contamination-reducing manufacturing systems.

What happened: - The Business Research Company projected the bioprocess containers market will rise from $6.39 billion in 2025 to $8.2 billion in 2026. - The report forecasts the market will reach $22.19 billion by 2030. - The company said the market is expanding because of biopharmaceutical manufacturing growth and demand for sterile processing solutions. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region through the forecast period.

The details: - Bioprocess containers are single-use vessels used to handle sterile liquids in biopharmaceutical production. - The containers store and manage liquid cell culture media, reagents and buffers. - The containers also serve as containment and storage units for intermediate and final products generated during biomanufacturing. - The report said growth is being supported by wider adoption of disposable bioprocess systems and the availability of advanced polymer materials. - The forecast also points to increased investment in cell and gene therapy production, modular bioprocessing facilities and contract biomanufacturing. - The market is expected to benefit from a stronger focus on sustainable bioprocessing practices and scalable manufacturing platforms. - Single-use bioprocessing, flexible manufacturing and sterile liquid handling are identified as major trends. - The report also flags efforts to reduce contamination risk. - The market coverage includes Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 edition of the report adds market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables. - The release included links to a free sample of the report and the full report.

Between the lines: - The forecast suggests bioprocess container demand is tied less to a single product category and more to the broader shift toward modular, lower-risk and more scalable biologics manufacturing. - The emphasis on single-use systems points to an industry preference for speed and flexibility over traditional reusable infrastructure. - The regional split suggests North America remains the current center of gravity, while Asia-Pacific is moving into a faster expansion phase. - June 2024 data cited from Cardinal Health showed 40 FDA-approved biosimilar products in 2023, with 25 commercially available in the US, up from 33 biosimilars in 2022.

What's next: - The market is expected to keep expanding as cell and gene therapy manufacturing grows. - Contract biomanufacturing and modular facility buildouts are likely to remain key demand drivers. - Further adoption of single-use and sterile liquid handling systems should continue if biomanufacturers keep prioritizing contamination control and scalability.

The bottom line: - The bioprocess containers market is on a steep growth path, and the biggest winners are likely to be suppliers serving biologics, biosimilars and advanced therapy manufacturing.